Abilify. Buy more. Save more.

Where to buy Abilify tablets no rx

admin — Fri, 02 Jan 2009 11:51:03 +0000

Abilify is an antipsychotic medication. It works by changing the actions of chemicals in the brain. Abilify is used for treatment the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression). It is also used together with other medications to treat major depressive disorder in adults.Buy cheap Abilify online without prescriptionBefore you take Abilify, tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by Abilify.Store Abilify tablets at room temperature away from moisture and heat.Take Abilify exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.Do not take aripiprazole for longer than 6 weeks unless your doctor has told you to. Take each dose with a full glass of water.Abilify can be taken with or without food. Abilify is usually taken once a day. Follow your doctor ’s instructions.Seek emergency medical attention if you think you have used too much of this medicine. Overdose symptoms may include drowsiness, vomiting, agitation, aggression, confusion, tremors, fast or slow heart rate, seizure (convulsions), trouble breathing, feeling light-headed, or fainting.

Chain Drug Review - New label

admin — Tue, 30 Dec 2008 18:06:02 +0000

Bristol-Myers Squibb Co. has been given FDA approval of a new label for Sprycel. The new designation recommends a 100-mg starting dose for the product, which treats chronic myeloid leukemia. The company has also announced clearance of Abilify as the first medication for add-on treatment of major depressive disorder.

Related Results

Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionNew ABILIFY formulation

Drug Cost Management Report - The FDA has approved Abilify™ tablets , a schizophrenia treatment by Bristol-Myers Squibb and Otsuka Pharmaceuticals - aripiprazole - Product News in Brief

admin — Sun, 28 Dec 2008 22:36:04 +0000

* The FDA has approved Abilify[TM] tablets (aripiprazole), a schizophrenia treatment by Bristol-Myers Squibb and Otsuka Pharmaceuticals. There is no cure for the devastating brain disorder affecting 2.2 million Americans, but it is treatable, and Abilify has demonstrated a favorable side-effect profile in clinical trials.

Related Results

Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionNew ABILIFY formulation

Psychiatric drugs account for over 12% of PBM spending, higher than any other single therapeutic category, according to AIS’ third quarter 2002 survey of PBMs. Information: www.abilify.com.
COPYRIGHT 2002 Atlantic Information Services, Inc.
COPYRIGHT 2003 Gale Group

Clinical Psychiatry News - Abilify available as oral solution

admin — Tue, 23 Dec 2008 14:56:07 +0000

An oral solution formulation of Abilify (aripiprazole) is now available. Abilify is indicated for the treatment of schizophrenia and for the treatment of acute manic and mixed episodes associated with bipolar disorder. For more information, contact Otsuka America Pharmaceutical Inc., by visiting www.abilify.com, or by calling 800-321-1335.

Related Results

Abilify approvalAbilify approvalNew AbilifyNew ABILIFY formulationAbilify wins clearance

Behavioral Healthcare - New ABILIFY formulation

admin — Sun, 21 Dec 2008 09:16:04 +0000

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd., have launched ABILIFY[R] DISCMELT[TM] (aripiprazole) Orally Disintegrating Tablets, an oral form of the antipsychotic medication aripiprazole that disintegrates rapidly in the mouth. The FDA approved ABILIFY DISCMELT on June 7. For full prescribing information, including boxed warning, visit www.abilify.com.

Related Results

Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionAbilify wins clearance

[ILLUSTRATION OMITTED]
COPYRIGHT 2006 Vendome Group LLC
COPYRIGHT 2008 Gale, Cengage Learning

Shared Psychotic Disorder Causes Symptoms Information With Treatment

admin — Thu, 18 Dec 2008 08:16:02 +0000

Shared psychotic disorder has also been referred to by other names such as psychosis of association, contagious insanity, infectious insanity, double insanity, and communicated insanity. This disorder usually occurs only in long-term relationships in which one person is dominant and the other is passive. In most cases, the person in whom the delusions are induced is dependent on or submissive to the person with the psychotic disorder. The people involved often are reclusive or otherwise isolated from society and have close emotional links with each other. The disorder also can occur in groups of individuals who are closely involved with a person who has a psychotic disorder. The disturbance is not better accounted for by another Psychotic Disorder (e.g., Schizophrenia) or a Mood Disorder With Psychotic Features and is not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition. The dominating primary case is most commonly represented by persons with schizophrenia, delusions, or mood disorders. In Western countries, both the original delusions in the dominant person and the induced delusions in the submissive person are usually chronic and either persecutory or grandiose in nature. In Japan, acute psychotic reactions have been noted to be delusions of a religious nature.

Causes of Shared Psychotic Disorder

Common Causes and Risk factors of Shared Psychotic Disorder

Social Isolation.

Stress.

Signs and Symptoms of Shared Psychotic Disorder

Sign and Symptoms of Shared Psychotic Disorder

Delusions.

Hallucinations.

Disorganized speech.

Grossly disorganized or catatonic behavior.

Treatment of Shared Psychotic Disorder

Common Treatment of Shared Psychotic Disorder

Atypical newer neuroleptics are the accepted mode of treatment for the spectrum of these disorders.

Newer-generation anticonvulsants are also highly effective for shared psychotic disorder.

Olanzapine/fluoxetine (Symbyax), aripiprazole (Abilify), and quetiapine (Seroquel) are extremely effective in these cases.

Antipsychotic medications also useful for Shared Psychotic Disorder

psychotherapy treating Shared Psychotic Disorder

Family therapy should also be considered to re-establish the nuclear family and to provide social support to modify old family dynamics.

Do not use illegal drugs or drink alcohol, especially when you are taking medicine for this condition.

Antipsychotic Drugs: OK for Dementia Patients?

admin — Sat, 13 Dec 2008 15:11:03 +0000

Oct. 18, 2005 — A new generation of antipsychotic drugs may slightly increase the risk of death when used to treat common behavioral and psychological problems in people with dementia.
The new drugs include Abilify, Zyprexa, Seroquel, and Risperdal.
A new review of clinical trials that treated people with dementia shows 3.5% of those prescribed the drugs died compared with 2.3% of those who took a placebo.
Researchers say most elderly people with dementia develop aggression, delusions, and other psychiatric symptoms; antipsychotic drugs are commonly used to treat those symptoms.
In the last decade a new generation of antipsychotic drugs has largely replaced the older conventional antipsychotics and has become the preferred treatment for behavioral problems associated with dementia. The older generation of drugs was associated with more pronounced side effects.
But researchers say concerns have arisen about possibly increased risk for death, stroke, and quickened mental decline.
Death Risk Tied to Common Dementia Treatment
In the study, which appears in The Journal of the American Medical Association, researchers analyzed information from 15 clinical trials of new antipsychotic drugs in treating people with dementia to see if there was any increased risk of death.
The results showed that death occurred more often among participants who were randomly assigned to receive one of the new antipsychotic drugs than those who received a placebo.
Researchers say most of the studies were 10 to 12 weeks long, and the fact that an increase in the risk of death as well as cerebrovascular events, such as stroke, was found in this short time period is concerning and suggests that these drugs should be used with care.
What to Do
In an editorial that accompanies the study, Peter V. Rabins, MD, MPH, and Constantine G. Lyketsos, MD, MHS, of Johns Hopkins Medical Institutions in Baltimore, say antipsychotic drugs are used to treat the psychological and behavioral symptoms that affect 60% to 90% of people with dementia.
In light of these results, they say other possible causes of behavioral and psychological problems, such as untreated or undertreated medical illnesses, overmedication, and lack of engaging activities, should be considered before treating these symptoms in people with dementia.
In addition, the risks and benefits of treatment with antipsychotic drugs should be weighed for each person. If antipsychotic drugs are prescribed, then careful monitoring is necessary.

Bristol-Myers Squibb Agrees to Pay More Than $9 Million to Massachusetts Medicaid Program to Settle Allegations of Improper Marketing and Business Practices

admin — Sun, 07 Dec 2008 07:21:03 +0000

BOSTONJuly 15, 2008– Attorney General Martha
Coakley’s Office has entered into an agreement with
international pharmaceutical manufacturer Bristol-Myers Squibb
Company (BMS) to settle a variety of allegations of improper sales,
marketing and price reporting practices. Under the terms of
the settlement, BMS will pay $9,214,659.43 to the Massachusetts
Medicaid Program.

“The Massachusetts Medicaid program expects health care
providers, both large and small, to operate with honesty and
integrity,” Attorney General Martha Coakley said.
“Our office will continue to work in collaboration with our
partners in state and federal law enforcement to identify and
eliminate fraudulent marketing and pricing schemes that drain
taxpayer dollars from an already overburdened health care
system.”
The agreement is the result of a four-part, seven-year
investigation that began in 2001, and was coordinated with the
federal government and other state Attorneys General involving BMS
and Apothecon, Inc., a former BMS subsidiary that produced and
marketed generic pharmaceutical products. The claims
addressed in the investigation arose from nine separate
whistle-blower lawsuits filed in various jurisdictions around the
country, and a voluntary disclosure by BMS of potential violations
of state and federal anti-kickback laws. The joint
investigation was conducted by the U.S. Department of Justice, the
U.S. Attorney’s Office for the District of Massachusetts, and
a national Medicaid Fraud team which includes attorneys and
investigators from Massachusetts, Ohio, New York, New Mexico,
Vermont and Pennsylvania. There were four distinct
components of the investigation:

Price Reporting

BMS was alleged to have deliberately and falsely inflated its
reported Average Wholesale Prices for sixteen Apothecon generic
drugs and seven BMS infusion therapy products. Government
health insurance programs commonly rely on these reported prices in
setting drug reimbursement amounts, and the improper overstatement
of these prices causes overpayments by the Medicare and Medicaid
programs.

Kickbacks

Both BMS and Apothecon were investigated for failure to comply
with the terms of federal and state anti-kickback statutes.
Apothecon was alleged to have paid improper inducements to
pharmacies and wholesalers in order to increase the market share of
its products to the disadvantage of its many generic competitors,
and BMS was alleged to have engaged in similar conduct to promote
sales of its innovator products over the therapeutic alternatives
developed and marketed by its brand-name competitors. In
addition, in the course of implementing marketing initiatives, BMS
offered substantial savings to pharmacies and wholesalers,
purportedly as legitimate incentives to improve the formulary
status of the entire Apothecon product line. Government
investigators charged, however, that these “discounts”
were in fact improperly linked to purchases of a number of
BMS’s blockbuster brand name drugs.

Off-label marketing of Abilify

Abilify is BMS’s entry in the lucrative market for
atypical anti-psychotic drugs, and was approved by the FDA in 2002
for the treatment of schizophrenia in adults and in 2004 for the
treatment of adult bipolar disorder. This phase of the
investigation focused on allegations that BMS had instructed its
sales staff to promote the prescribing of Abilify for pediatric
uses and for the treatment of dementia when the drug had not
received FDA approval for use by children or as a therapy for
dementia.

Serzone Rebate Violations

The settlement also resolves allegations that BMS sold its
anti-depressant Serzone to California-based HMO Kaiser Permanente
at a deep discount and concealed the sales data from the federal
government, thereby improperly reducing the amount of Medicaid
rebates the company paid to the states.

The U.S. Department of Justice announced the federal component of
this settlement in September 2007. The total value of the
combined federal and state settlements to the state Medicaid
programs nationwide is approximately $389 million, with more than
$9 million allocated to Massachusetts Medicaid. In addition
to the payments to the federal government and the states, BMS has
agreed to the terms of a Corporate Integrity Agreement, which will
include provisions to ensure that BMS discontinues the conduct that
was the subject of the government’s investigation, and will
require ongoing oversight by the federal government of the
company’s marketing, sales and price reporting
practices.

The Massachusetts portion of the investigation was handled by
Assistant Attorney General Robert Patten, with assistance from Data
Analyst Anthony Megathlin, both of Attorney General Martha
Coakley’s Medicaid Fraud Division. The settlement was
the result of negotiations jointly conducted by the Department of
Justice, the United States Attorney’s Office for the District
of Massachusetts and the National Association of Medicaid Fraud
Control Units, with representatives of the Massachusetts, Ohio,
Vermont, New Mexico and New York attorney generals’ offices
representing the states in the negotiations.

Contact:
Harry Pierre
(617) 727-2543

Business Wire - Research and Markets: 2006 Market Research Available On Bristol-Myers Squibb Showcasing Its Current Growth Drivers

admin — Thu, 04 Dec 2008 14:51:03 +0000

DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c47514) has announced the addition of Bristol-Myers Squibb Prospects to 2010 from Espicom Business Intelligence to their offering.
Headquartered in New York, Bristol-Myers Squibb (BMS) is involved in the research and development of treatments for conditions such as heart disease, high blood pressure, stroke, diabetes, cancer, HIV/AIDS, depression, schizophrenia and pain. The company’s research and development efforts are principally focused on Oncology, Affective (Psychiatric) Disorders and Metabolics.
Current Growth Drivers

Most Popular
10 Jobs That Pay $30 An Hour
13 Job Interview Mistakes To Avoid
5 Regular Mistakes In Public Speaking
Public Speaking: 7 Secrets Of Great Public Speakers
3 Questions No Job Seeker Ever Wants To Be Asked?

Plavix (clopidogrel), a platelet aggregation inhibitor, is BMS’ largest selling product and continues to make substantial year-on-year sales growth. The product benefits from co-development and co-commercialisation with sanofi-aventis in a number of markets worldwide. Since its first approval in 1997, Plavix has been prescribed for around 48 million patients.
Similarly, Avapro/Avalide (irbesartan), an angiotensin II receptor agonist indicated for the treatment of hypertension and diabetic neuropathy, was co-developed and co-marketed with sanofi-aventis in several markets and also has demonstrated steady market gains since its launch.
Abilify (aripiprazole), indicated for the treatment of schizophrenia and related conditions, is the company’s flagship Affective Disorders product. The product was licensed from Otsuka, with whom BMS co-promotes Abilify in several markets, and has made strong sales increases since it became part of BMS’ product portfolio.
Erbitux (cetuximab) was licensed from ImClone Systems to become BMS’ first biological product. It is used in the treatments of various cancers and in March 2006, it became the first new treatment for squamous cell head and neck cancer in nearly three decades.
Reyataz (atazanavir), a potent azapeptide inhibitor of HIV protease, is the first once-daily protease inhibitor to be approved by the FDA. In 2005, it demonstrated the most significant growth of BMS’ pharmaceutical products, with sales increasing by nearly 70 per cent from the previous year.
These pharmaceutical company intelligence reports provide a full review of the company’s activities together with five-year sales forecasts for its key products. The company’s financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company’s product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
Bristol-Myers Squibb is involved in the research and development of treatments for conditions such as heart disease, high blood pressure, stroke, diabetes, cancer, HIV/AIDS, depression, schizophrenia and pain. This report provides a full review of the company’s activities together with sales forecasts for key products to 2010.
Content Outline:
Principal Operating Results
Latest Results
EXECUTIVE SUMMARY
Introduction
Current Growth Drivers
Key Late-Stage Products
Financial Performance 2005
Sales and Market Position
Income
Expenditure
Capital Expenditure
Capital Expenditure By Business Area
R&D Expenditure
Divisional Performance
Sales By Business Segment
Operating Income By Business Segment
Year-End Assets By Business Segment
Geographic Performance
Sales By Geographic Area
Year-End Assets By Geographic Area
Company Strategy
Mergers, Acquisitions and Divestitures
Key Agreements
Production
Employees
Product / R&D Overview
Key Products
Recent Product Launches
Recent Product Approvals
Discontinued Products
UFT
R&D Strategy
Key R&D Projects
R&D Pipeline Overview
Discontinued R&D projects
Basulin
E2F Decoy
Pargluva
Ravuconazole (BMS-207147, ER-30346)
Sales Forecasts
Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT 27
APPENDIX 1 - FINANCIAL PERFORMANCE
Full Year Results 2005
APPENDIX 2 - KEY CORPORATE EVENTS
APPENDIX 3 - KEY AGREEMENTS
APPENDIX 4 - INFRASTRUCTURE
APPENDIX 5 - KEY PHARMACEUTICAL
SUBSIDIARIES / JOINT VENTURES
APPENDIX 6 - PRODUCT INDEX
Index of Tables
Index of Charts
For more information visit http://www.researchandmarkets.com/reports/c47514.
COPYRIGHT 2006 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Different Types of Medications for Schizophrenia

admin — Tue, 02 Dec 2008 11:16:02 +0000

First, and the most important is antipsychotic medication. It includes the classic antipsychotic drugs and new generation of antipsychotic medication.
Chlorpromazine, haloperidol and thioridazine are the classic antipsychotic drugs. They have importend side effects, such as: heart palpitations, akathisia, constipation, dry mouth, urinary retention, sexual problems, dizziness, muscle twitches and tics. Because of this annoying side effects, this class of medication was replaced with the new generation of antipsychotic medication.
Risperidone (Risperdal), olanzapine (Zyprexa), quetiapine (Seroquel), ziprasidone (Geodon) and aripiprazole (Abilify) are the most used medications from the new generation. They don’t have side effects of the classics one, but they have side effects to, and these are: diabetes and heart disease predisposition and weight gain.
Antipsychotic medication is split in two types: pills and injectable medication.
Antianxiety medication is very used in schizophrenia treatment because anxiety is a common and annoying symptom at this patients. Once this problem is solved, patients can appear as normal persons, with a normal life and who can work and do almost everything they where doing before. So, depression is less a problem, and we avoid using antidepressants medication.
If is necessary, we can use other medication to reduce side effects of antipsychotic medication, but only if is imperious necessary, because this medication can have side effects too.
In present are used both classic and new antipsychotic medication. The classic antipsychotic are used because they treat very well delusions, hallucinations, and confusion of schizophrenia.
Even antipsychotic medication is used with great results, sometimes is not enough. As an alternative, group therapy, family therapy and individual psychotherapy are used.
With the support of antipsychotic medication and psychotherapy, patients with schizophrenia can live almost a normal life, and only a small part of them need to be treated in special medical centers.